Schrödinger

It was a pleasure to host students from the Harvard Medical School Therapeutics Graduate Program at Schrödinger's Cambridge office last week. Schrödinger team members presented an overview of how our computational platform is deployed to accelerate collaborative and internal drug discovery projects, giving students a better understanding of real-world industry challenges. We are grateful for the opportunity to help prepare the next generation of scientists through in-person engagement and educational resources. Learn more about our online certification courses: https://lnkd.in/eCUuXUdM Explore our Teaching with Schrödinger initiative: https://lnkd.in/e9budee4

Schrödinger is excited to be participating in the AAPS 2024 PharmSci 360 conference taking place on October 20th – 23rd in Salt Lake City, Utah. Stop by our booth #2503 to learn how molecular modeling can enhance your formulations research, and join us for two presentations by Schrödinger scientists: • Monday, October 21, 10:00 – 10:30 AM MDT: "Coarse-grained modeling of nucleic acid-loaded lipid nanoparticle formulations" presented by Doug Grzetic, Senior Scientist I • Monday, October 21, 3:15 – 3:30 PM MDT: "Modernize your arsenal of formulation tools with physics-based molecular simulation" presented by Ben Coscia, Principal Scientist I Learn more: https://lnkd.in/eB9nTwji

Are you attending the Discovery on Target 2024 conference in Boston, Massachusetts? Schrödinger is presenting preclinical data for its research program that could potentially address the need for non-hormonal contraception. Learn more about our global health initiatives and our commitment to sustainability: https://hubs.li/Q02RDS3L0

Are you attending this year’s SEPAWA Congress in Berlin, Germany? Join our talk by Schrödinger's Jeffrey Sanders to learn how active learning technology, which incorporates physics-based simulation and experimental data in ML models, can help advance cosmetics R&D. Visit our booths 832 & 833 for demos, discussions, and inspiration. Learn more: https://hubs.li/Q02R8lHn0 #Schrodinger #MaterialsScience #Sustainability #Cosmetics

Schrödinger is excited to be participating in the Discovery on Target 2024 conference taking place September 30 – October 3 in Boston, Massachusetts. Stop by our booth #523 to speak with our scientists and discover how our computational platform can accelerate your drug discovery research. Learn more: https://hubs.li/Q02RxtM90

Schrödinger will be at this year’s Festival of Biologics on October 15-17th in Basel, Switzerland. Don't miss the presentation by Esam Abualrous, Advances in Structure-Based Computational Modeling and Collaborative Enterprise Informatics for Biologics. Stop by our booth 640 to speak with Schrödinger scientists and discover how computational modeling can accelerate your biologics discovery. Learn more: https://hubs.li/Q02R3P810

Join us at BioTechX Europe taking place on October 9th – 10th in Basel. Don't miss the presentation by Schrödinger's CTO, Pat Lorton, exploring how a ‘predict-first’ approach to drug discovery allows teams to explore significantly more chemical space, resulting in a highly interactive, computationally-driven DMTA cycle. Learn about the digital chemistry strategy used by Schrödinger’s therapeutics group in multiple clinical-stage drug discovery programs, and get an introduction to the upcoming expansion of our computational platform to predict toxicology risk in early-stage drug discovery. Learn more: https://hubs.ly/Q02Q99d10

We are honored to receive a $2.8 million research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance our LRRK2 inhibitor program. Mutations in the LRRK2 gene are the most common genetic cause of Parkinson’s disease. Schrödinger has generated multiple proprietary cryo-EM structures of LRRK2, which coupled with our transformative computational platform, provides our therapeutics team with new opportunities to advance our research. This generous funding will allow us to investigate novel modes of safely inhibiting the LRRK2 protein. We appreciate the support of MJFF and the continued dedication of our LRRK2 team to advance this program with the goal of finding a much needed cure for patients with Parkinson’s disease. Explore our pipeline to learn more: https://hubs.li/Q02PQ6lH0 #Parkinsons #LRRK2 #MJFF

On September 12th, Schrödinger’s Agus Rodriguez-Granillo will join other leading drug developers to share unique insights into how they are harnessing targeted protein degraders and induced proximity to develop next-gen therapeutics. This MicroSummit includes 7 lightning talks and opportunities for 1:1 discussions with other attendees. To join, register here: https://hubs.li/Q02PpxvM0

Physics-based modeling coupled with AI/ML optimizes both predictive accuracy and computational efficiency for modern materials discovery. Join Schrödinger’s Anand Chandrasekaran on Sept 24th or 26th to explore the latest technologies and case studies employing this combined approach to design materials and formulations across diverse materials science applications, from battery electrolytes and fuel mixtures to thermoplastics and OLED devices. Register now: https://hubs.ly/Q02Pd1DN0 #Schrodinger #MaterialsScience #DigitalChemistry #Machine Learning